1 Min Read
Feb 12 (Reuters) - Reata Pharmaceuticals Inc:
* REATA ANNOUNCES IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE METHYL MAINTAINED FOR TWO YEARS IN PAH PATIENTS FROM LARIAT TRIAL Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.